GlassScriptPhysician profile
Thomas J Melvin
NPI 1467989855
$4,036.68
in general payments reported to CMS, 2019-2025
8 companies · $809 in 2025
The $809 reported for 2025 was less than what a typical Thoracic Surgery (Cardiothoracic Vascular Surgery) provider received nationally (typical 2025 total: $796).
See the full distribution for Thoracic Surgery (Cardiothoracic Vascular Surgery)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $99.25 · 2023: $2,846 · 2024: $283 · 2025: $809.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,428 · Food and Beverage: $1,423 · Education: $85.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,428.33 |
| Food and Beverage | $1,423.26 |
| Education | $85.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pinnacle Biologics, INC | $2,770.45 | 2023-2025 | Photofrin |
| Ethicon INC. | $441.53 | 2024-2025 | Monarch Platform |
| Intuitive Surgical, INC. | $245.82 | 2023-2024 | |
| Medtronic, INC. | $140.70 | 2023-2025 | Signia, Penditure |
| On Target Laboratories, INC | $131.40 | 2025 | Cytalux |
| Amgen INC. | $109.62 | 2025 | Krystexxa |
| Xeris Pharmaceuticals, INC. | $99.25 | 2021 | |
| Edwards Lifesciences Corporation | $97.91 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Melvin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.